The National Institute for Health and Care Excellence (NICE) has recommended Blueprint Medicines’ Ayvakyt (avapritinib) to ...

The announcement comes just a few months after WHO released its 2024 Bacterial Priority Pathogens List, which highlights the ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the European Commission (EC) to treat eosinophilic ...

The US Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi (minocycline hydrochloride extended release capsules 40mg) to treat inflammatory lesions of rosacea in adults. Affecting ...

GCI Health has announced the appointment of Annalise Coady as president, UK market lead and EMEA head of growth. Coady brings over two decades of experience in building and scaling marketing ...

Johnson & Johnson (J&J) has announced that its pan-FGFR tyrosine kinase inhibitor Balversa (erdafitinib) has been granted marketing authorisation by the Medicines and Healthcare products Regulatory ...

UCB has announced “encouraging data” from a phase 2a study of its investigational anti-tau antibody bepranemab in Alzheimer’s disease (AD) patients. The TOGETHER study has been evaluating the safety, ...

GSK has announced that it will be expanding its immunology pipeline by acquiring a clinical-stage T cell-engager from Chimagen Biosciences in a deal worth $850m. GSK said it plans to develop and ...

AstraZeneca’s Fasenra (benralizumab) has been approved by the European Commission (EC) to treat eosinophilic granulomatosis with polyangiitis (EGPA), a rare immune-mediated inflammatory disease that ...

Principal Medical Writer, Dr Alexandra Loveday explores the importance of storytelling in health communications. Medical facts alone don’t change minds—stories do. Originating from the broader ...

EatMoreFruit, a UK top 10 independent healthcare communication agency, today announced the launch of its European Network to support new and existing clients across the diagnostics, med tech, life ...

Novo Nordisk has shared promising results from a late-stage study of semaglutide in patients with metabolic ...